Company: BIAF
Filing Date: 2025-04-15
Form Type: PRE 14A
Source: 0001641172-25-004857
Chunk: 17

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: PRE 14A
Chunk 17
---
 the rules and regulations of the Nasdaq Stock Market. The Trading Policy provides our standards on trading and
causing the trading of our securities while in possession of confidential information. It prohibits trading in certain circumstances and
applies to us and all of our directors, officers and employees who have access to material nonpublic information (“MNPI”)
about the Company and from giving MNPI to others who may trade on the basis of such information. Under the policy, Timothy Zannes, the
Company’s Executive Vice President, Secretary, and General Counsel, is designated as the Company’s Insider Trading Compliance
Officer (the “Compliance Officer”). Prior to engaging in transfers of Company securities intended to comply
with the affirmative defense provided under Rule 10b5-1 promulgated under the Exchange Act, employees, officers, and directors must receive
the Compliance Officer’s approval. The Trading Policy is annexed as an exhibit to our Annual Report on Form 10-K for the year ended
December 31, 2024.

Prohibition against Short Sales and Hedging

Pursuant to our Insider Trading Policy, we prohibit
our employees, officers and directors from trading in any interest or position relating to the future price of Company securities, such
as a put, call or short sale (including a short sale “against the box”).

Role of the Board in Risk Oversight

One of the key functions of the Board is informed
oversight of the Company’s risk management process. The Board does not have a standing risk management committee but rather administers
its oversight function directly through the Board as a whole and through its standing committees that address risks inherent in their
respective oversight areas. In particular, the Board is responsible for monitoring and assessing strategic risk exposure. The Audit Committee
has the responsibility to consider and discuss (i) the Company’s major financial risk exposures and the steps management has taken
to monitor and control these exposures, which includes establishing guidelines and policies to govern the process by which risk assessment
and management is undertaken and (ii) policies regarding information technology security and protection from cyber risks The Audit Committee
also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of the Company’s external
audit function.

The Nominating and Corporate Governance Committee
monitors the effectiveness of the Company’s corporate governance guidelines. The Compensation Committee assesses and monitors whether
any of the Company’s compensation policies and programs has the potential to encourage excessive risk-taking. While each committee
is responsible for evaluating